文献速递临床试验与 GCP基础与转化研究

替格瑞洛与预适应在稳定性冠心病患者中的随机初步临床试验

Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial.
PubMed 文献 · Trials · 2020-02-17

本研究为前瞻性、开放标签、随机初步试验,计划纳入100例稳定多支冠状动脉疾病患者,按1:1随机接受替格瑞洛或氯吡格雷治疗,比较经皮冠状动脉介入治疗(PCI)中球囊扩张时ST段抬高差值等指标,以评估替格瑞洛能否触发缺血预适应并改善微血管功能。

要点

  • 替格瑞洛可能通过增加腺苷生物利用度触发缺血预适应。
  • 主要终点为两步序贯球囊扩张时ST段抬高差值(毫米)。
  • 次要终点包括冠状动脉血流储备、微血管阻力指数及心绞痛评分。

核心结论

  • 替格瑞洛可能较氯吡格雷改善缺血耐受和微血管功能,并可能转化为更好的长期临床结局。

研究设计与样本

  • 前瞻性、开放标签、随机初步试验,计划纳入100例稳定多支冠状动脉疾病需分期FFR指导PCI的患者。
  • 参与者按1:1随机接受替格瑞洛(负荷180 mg,维持90 mg每日两次)或氯吡格雷(负荷600 mg,维持75 mg每日一次),从计划PCI前3至1天开始用药。
  • PCI操作者对随机分组设盲。
  • 主要终点为 culprit 血管两步序贯球囊扩张期间经冠状动脉心电图评估的ST段抬高差值(毫米)。

关键数值与推荐

  • 主要终点为两次球囊扩张间ST段抬高的差值(毫米)。
  • 次要终点包括 culprit 血管和参考血管在PCI结束时测量的冠状动脉血流储备(CFR)、微血管阻力指数(IMR)和FFR的变化,以及扩张期间的心绞痛评分。
  • 基于负性FFR率高达30%和脱落率高达10%,预计检测研究组间重复球囊扩张后ST段抬高平均变化的绝对差异为4 mm。

局限性

  • 本研究为开放标签、初步试验,样本量有限且计划纳入100例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ticagrelor is a reversibly binding, direct-acting, oral, P2Y12 antagonist used for the prevention of atherothrombotic events in patients with coronary artery disease (CAD). Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Meanwhile, adenosine plays an important role in triggering ischemic preconditioning through the activation of the A1 receptor. Therefore, an increase in ticagrelor-enhanced adenosine bioavailability may confer beneficial effects through mechanisms related to preconditioning activation and improvement of coronary microvascular dysfunction. METHODS: To determine whether ticagrelor can trigger ischemic preconditioning and influence microvascular function, we designed this prospective, open-label, pilot study that enrolled patients with stable multivessel CAD requiring staged, fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI). Participants will be randomized in 1:1 ratios either to ticagrelor (loading dose (LD) 180 mg, maintenance dose (MD) 90 mg bid) or to clopidogrel (LD 600 mg, MD 75 mg) from 3 to 1 days before the scheduled PCI. The PCI operators will be blinded to the randomization arm. The primary endpoint is the delta (difference) between ST segment elevations (in millimeters, mm) as assessed by intracoronary electrocardiogram (ECG) during the two-step sequential coronary balloon inflation in the culprit vessel. Secondary endpoints are 1) changes in coronary flow reserve (CFR), index of microvascular resistance (IMR), and FFR measured in the culprit vessel and reference vessel at the end of PCI, and 2) angina score during inflations. This study started in 2018 with the aim of enrolling 100 patients. Based on the rate of negative FFR up to 30% and a drop-out rate up to 10%, we expect to detect an absolute difference of 4 mm among the study arms in the mean change of ST elevation following repeated balloon inflations. All study procedures were reviewed and approved by the Ethical Committee of the Catholic University of Sacred Heart. DISCUSSION: Ticagrelor might improve ischemia tolerance and microvascular function compared to clopidogrel, and these effects might translate to better long-term clinical outcomes. TRIAL REGISTRATION: EudraCT No. 2016-004746-28. No. NCT02701140. TRIAL STATUS: Information provided in this manuscript refers to the definitive version (n. 3.0) of the study protocol, dated 31 October 2017, and includes all protocol amendments. Recruitment started on 18 September 2018 and is currently ongoing. The enrollment is expected to be completed by the end of 2019. TRIAL SPONSOR: Fondazione Policlinico Universitario A. Gemelli - Roma, Polo di Scienze Cardiovascolari e Toraciche, Largo Agostino Gemelli 8, 00168 Rome, Italy.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. D'Amario D, Restivo A, Leone AM, et al. Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial. Trials. 2020. PMID: 32066489. doi:10.1186/s13063-020-4116-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。